TechnoDerma announced the appointment of key members of the Scientific Advisory Board, Professor Xiang Leihong, a dermatologist at Fudan University School of medicine, Dr. John Mao, a senior drug R & D expert in the San Francisco Bay area, Professor G
TDM-105795 is the Lead Small Molecule Drug in Topical Formulation
Established in 2014, Technoderma is a leader in the research and development of innovative drugs for skin indications. The success of this round of financing provides a strong support for the company to rapidly advance the preclinical research and
From left to right: Wenkui Fang,Ph.D, Zengquan Wang,Ph.D and Guanqun Li,M.D.Ph.D.
TechnoDerma has built a number of dermatological disease pipelines through independent R&D and license-in. The company is gradually growing into a globally-positioned innovative drug research and development company specialized in dermatology. TechnoD
On July 1, 2016, TechnoDerma announced the completion of a multi-million yuan Angel round of financing. The completion of financing marks the official launch of the startup company and its innovative small molecule drug discovery program for the treatment
